Who are Early Vasopressin's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Terlipressin & then Dummy, somatostatin or terlipressin, Misoprostol + vasopressin, norepinephrine+vasopressin, MediCabilis CBD Oil, terlipressin (vasoconstrictor).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/early-vasopressin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Early Vasopressin — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Early Vasopressin (Early Vasopressin) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Vasopressor agent. Area: Critical Care / Cardiovascular.

phase 3 Vasopressor agent V1 receptor Critical Care / Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Early Vasopressin (Early Vasopressin) — Hospital do Coracao. Early Vasopressin is a vasopressin analog that acts as a vasoconstrictor to increase blood pressure and peripheral vascular resistance in acute hypotensive states.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Early Vasopressin TARGET	Early Vasopressin	Hospital do Coracao	phase 3	Vasopressor agent	V1 receptor
Terlipressin & then Dummy	Terlipressin & then Dummy	Aga Khan University	marketed	Vasopressin analog	Vasopressin V1 receptor
somatostatin or terlipressin	somatostatin or terlipressin	National Science and Technology Council, Taiwan	marketed	Vasoactive peptide	Somatostatin receptors (SSTR) / Vasopressin V1 receptor
Misoprostol + vasopressin	Misoprostol + vasopressin	University Hospital of the West Indies	marketed	Combination therapy: prostaglandin analog + vasopressor	Prostaglandin receptor (EP3/EP4) and vasopressin V1 receptor
norepinephrine+vasopressin	norepinephrine+vasopressin	Peking Union Medical College Hospital	marketed	Vasopressor combination	Alpha-1 adrenergic receptor, beta-1 adrenergic receptor, vasopressin V1 receptor
MediCabilis CBD Oil	MediCabilis CBD Oil	Gold Coast Hospital and Health Service	marketed	Cannabinoid	CB1 receptor, CB2 receptor, 5-HT1A receptor, TRPV1 receptor (multiple targets)
terlipressin (vasoconstrictor)	terlipressin (vasoconstrictor)	National Science and Technology Council, Taiwan	marketed	Vasopressin analog	Vasopressin V1 receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Vasopressor agent class)

Assistance Publique - Hôpitaux de Paris · 1 drug in this class
Hospital do Coracao · 1 drug in this class
Massachusetts General Hospital · 1 drug in this class
Prisma Health-Upstate · 1 drug in this class
The Cleveland Clinic · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Early Vasopressin — Competitive Intelligence Brief. https://druglandscape.com/ci/early-vasopressin. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing